vs
READING INTERNATIONAL INC（RDI）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
READING INTERNATIONAL INC的季度营收约是REGENXBIO Inc.的1.7倍（$50.3M vs $30.3M），READING INTERNATIONAL INC净利率更高（-5.1% vs -221.3%，领先216.2%），REGENXBIO Inc.同比增速更快（43.0% vs -14.2%），READING INTERNATIONAL INC自由现金流更多（$4.1M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 5.6%）
雷丁公司是总部位于美国费城的铁路企业，1924年起在宾夕法尼亚州东部及周边各州提供客运与货运运输服务，直至1976年被联合铁路公司收购。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
RDI vs RGNX — 直观对比
营收规模更大
RDI
是对方的1.7倍
$30.3M
营收增速更快
RGNX
高出57.2%
-14.2%
净利率更高
RDI
高出216.2%
-221.3%
自由现金流更多
RDI
多$56.9M
$-52.8M
两年增速更快
RGNX
近两年复合增速
5.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $50.3M | $30.3M |
| 净利润 | $-2.6M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | -1.9% | -190.0% |
| 净利率 | -5.1% | -221.3% |
| 营收同比 | -14.2% | 43.0% |
| 净利润同比 | -14.5% | -31.2% |
| 每股收益（稀释后） | $-0.11 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RDIRGNX
| Q4 25 | $50.3M | $30.3M | ||
| Q3 25 | $52.2M | $29.7M | ||
| Q2 25 | $60.4M | $21.4M | ||
| Q1 25 | $40.2M | $89.0M | ||
| Q4 24 | $58.6M | $21.2M | ||
| Q3 24 | $60.1M | $24.2M | ||
| Q2 24 | $46.8M | $22.3M | ||
| Q1 24 | $45.1M | $15.6M |
净利润RDIRGNX
| Q4 25 | $-2.6M | $-67.1M | ||
| Q3 25 | $-4.2M | $-61.9M | ||
| Q2 25 | $-2.7M | $-70.9M | ||
| Q1 25 | $-4.8M | $6.1M | ||
| Q4 24 | $-2.2M | $-51.2M | ||
| Q3 24 | $-7.0M | $-59.6M | ||
| Q2 24 | $-12.8M | $-53.0M | ||
| Q1 24 | $-13.2M | $-63.3M |
毛利率RDIRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率RDIRGNX
| Q4 25 | -1.9% | -190.0% | ||
| Q3 25 | -0.6% | -176.3% | ||
| Q2 25 | 4.8% | -296.3% | ||
| Q1 25 | -17.2% | 13.6% | ||
| Q4 24 | 2.6% | -242.1% | ||
| Q3 24 | -0.6% | -256.6% | ||
| Q2 24 | -16.4% | -251.3% | ||
| Q1 24 | -16.7% | -408.8% |
净利率RDIRGNX
| Q4 25 | -5.1% | -221.3% | ||
| Q3 25 | -8.0% | -208.3% | ||
| Q2 25 | -4.4% | -331.8% | ||
| Q1 25 | -11.8% | 6.8% | ||
| Q4 24 | -3.8% | -241.3% | ||
| Q3 24 | -11.7% | -246.3% | ||
| Q2 24 | -27.4% | -237.7% | ||
| Q1 24 | -29.4% | -405.4% |
每股收益（稀释后）RDIRGNX
| Q4 25 | $-0.11 | $-1.30 | ||
| Q3 25 | $-0.18 | $-1.20 | ||
| Q2 25 | $-0.12 | $-1.38 | ||
| Q1 25 | $-0.21 | $0.12 | ||
| Q4 24 | $-0.11 | $-0.99 | ||
| Q3 24 | $-0.31 | $-1.17 | ||
| Q2 24 | $-0.57 | $-1.05 | ||
| Q1 24 | $-0.59 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $10.5M | $230.1M |
| 总债务越低越好 | $185.1M | — |
| 股东权益账面价值 | $-18.2M | $102.7M |
| 总资产 | $434.9M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资RDIRGNX
| Q4 25 | $10.5M | $230.1M | ||
| Q3 25 | $8.1M | $274.2M | ||
| Q2 25 | $9.1M | $323.3M | ||
| Q1 25 | $5.9M | $267.9M | ||
| Q4 24 | $12.4M | $234.7M | ||
| Q3 24 | $10.1M | $255.5M | ||
| Q2 24 | $9.3M | $290.4M | ||
| Q1 24 | $7.5M | $338.7M |
总债务RDIRGNX
| Q4 25 | $185.1M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $202.7M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益RDIRGNX
| Q4 25 | $-18.2M | $102.7M | ||
| Q3 25 | $-12.1M | $161.5M | ||
| Q2 25 | $-7.7M | $213.7M | ||
| Q1 25 | $-8.1M | $274.2M | ||
| Q4 24 | $-4.4M | $259.7M | ||
| Q3 24 | $1.6M | $301.4M | ||
| Q2 24 | $6.5M | $348.3M | ||
| Q1 24 | $18.0M | $390.7M |
总资产RDIRGNX
| Q4 25 | $434.9M | $453.0M | ||
| Q3 25 | $435.2M | $525.2M | ||
| Q2 25 | $438.1M | $581.0M | ||
| Q1 25 | $441.0M | $490.9M | ||
| Q4 24 | $471.0M | $466.0M | ||
| Q3 24 | $495.7M | $519.1M | ||
| Q2 24 | $494.9M | $569.4M | ||
| Q1 24 | $494.9M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.3M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $4.1M | $-52.8M |
| 自由现金流率自由现金流/营收 | 8.2% | -174.0% |
| 资本支出强度资本支出/营收 | 0.3% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-2.9M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流RDIRGNX
| Q4 25 | $4.3M | $-52.3M | ||
| Q3 25 | $295.0K | $-56.0M | ||
| Q2 25 | $1.6M | $-49.3M | ||
| Q1 25 | $-7.7M | $33.6M | ||
| Q4 24 | $8.0M | $-31.6M | ||
| Q3 24 | $1.3M | $-40.5M | ||
| Q2 24 | $-10.4M | $-45.5M | ||
| Q1 24 | $-2.8M | $-55.5M |
自由现金流RDIRGNX
| Q4 25 | $4.1M | $-52.8M | ||
| Q3 25 | $-246.0K | $-56.5M | ||
| Q2 25 | $1.2M | $-49.7M | ||
| Q1 25 | $-8.0M | $32.6M | ||
| Q4 24 | $7.0M | $-32.7M | ||
| Q3 24 | $-1.1M | $-40.9M | ||
| Q2 24 | $-10.6M | $-46.0M | ||
| Q1 24 | $-4.7M | $-56.0M |
自由现金流率RDIRGNX
| Q4 25 | 8.2% | -174.0% | ||
| Q3 25 | -0.5% | -189.9% | ||
| Q2 25 | 1.9% | -232.8% | ||
| Q1 25 | -19.8% | 36.6% | ||
| Q4 24 | 12.0% | -154.2% | ||
| Q3 24 | -1.8% | -168.9% | ||
| Q2 24 | -22.7% | -206.2% | ||
| Q1 24 | -10.4% | -358.5% |
资本支出强度RDIRGNX
| Q4 25 | 0.3% | 1.7% | ||
| Q3 25 | 1.0% | 1.7% | ||
| Q2 25 | 0.6% | 1.8% | ||
| Q1 25 | 0.6% | 1.2% | ||
| Q4 24 | 1.7% | 5.1% | ||
| Q3 24 | 4.0% | 1.3% | ||
| Q2 24 | 0.5% | 2.1% | ||
| Q1 24 | 4.3% | 3.6% |
现金转化率RDIRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RDI
| Cinema Exhibition Segment | $46.9M | 93% |
| Real Estate Revenue | $3.4M | 7% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
